(IN BRIEF) The British Heart Foundation has awarded £7.1 million to fund the CHAIN consortium, a national PhD training programme focused on understanding the critical link between heart and brain diseases. Delivered collaboratively by the University of Manchester, University of … Read the full press release
Posted in Artificial Intelligence (AI), Business, Education, Financial, Healthcare, Industrial, Infrastructure & Utilities, Investment, Management, Marketing, Non Profit, Science, Technology, United Kingdom
Tagged Alastair Poole, artificial intelligence, atrial fibrillation, British Heart Foundation, cardiovascular disease, CHAIN consortium, data science, Deirdre Lane, Gina Galli, Healthcare Innovation, heart brain axis, Louise Kenny, Multidisciplinary CHAIN Programme Aims to Transform Understanding of Heart Brain Connections in Modern Medicine, multidisciplinary research, myocardial infarction, neurological disease, personalised medicine, PhD programme, University of Bristol, University of Liverpool, University of Liverpool Joins Major BHF-Funded Initiative to Train Future Leaders in Cardiovascular and Brain Science, University of Manchester, vascular dementia
(IN BRIEF) Roche has obtained CE mark approval for its Elecsys Neurofilament Light Chain blood test, which detects neuroinflammation in patients with relapsing-remitting multiple sclerosis. The minimally invasive test measures biomarkers of nerve damage, offering an alternative to traditional monitoring … Read the full press release
Posted in Business, Financial, Healthcare, Industrial, Investment, Management, Marketing, Pharma & Biotech, Science, Security & Safety, Switzerland, Technology
Tagged biomarkers, blood test, CE Mark, cobas instruments, diagnostics, Elecsys NfL, Elecsys NfL Approval Expands Access to Advanced MS Monitoring with Simple Blood Based Testing, Healthcare Innovation, Matt Sause, multiple sclerosis, neurofilament light chain, neuroinflammation, neurological disease, patient monitoring, relapsing remitting MS, Roche
(PRESS RELEASE) VALBY, Denmark, 22-Dec-2020 — /EuropaWire/ — Danish international pharmaceutical company, H. Lundbeck A/S (Lundbeck) announces that its marketing authorization application for Vyepti™ (eptinezumab-jjmr) has been accepted by the European Medicines Agency (EMA). The filing seeks approval to introduce … Read the full press release
Posted in Denmark, Healthcare, Marketing, News, Pharma & Biotech
Tagged calcitonin gene-related peptide, CGRP, Dr. Johan Luthman, EMA, eptinezumab-jjmr, European Medicines Agency, H. Lundbeck A/S, humanized monoclonal antibody, Juliane Lenzner, Lundbeck, marketing authorization, migraine, migraine preventive antibody, neurological disease, Palle Holm Olesen, preventative therapy, severe headaches, Vyepti™
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions. Here you can learn more about EuropaWire’s mission, achievements, services, etc.
HOW TO GET STARTED?